genotropin miniquick 400microgram powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 400microgram
genotropin miniquick 600microgram powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 600microgram
genotropin miniquick 800microgram powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 800microgram
genotropin miniquick 1.2mg powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 1.2mg
genotropin miniquick 1mg powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 1mg
genotropin miniquick 1.4mg powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 1.4mg
genotropin miniquick 1.6mg powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 1.6mg
genotropin miniquick 1.8mg powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 1.8mg
genotropin miniquick 2mg powder and solvent for solution for injection pre-filled disposable devices
pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 2mg
genotropin miniquick somatropin (rbe) 0.2mg/0.25ml powder for injection & diluent in prefilled syringe
pfizer australia pty ltd - somatropin, quantity: 0.8 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - indications: short stature due to decreased or failed secretion of pituitary growth hormone. indications as at 13 june 2003: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.